(Q30457615)

21 June 2017

1 reference

title

Investigational inhibitors of PTP4A3 phosphatase as antineoplastic agents (English)

1 reference

21 June 2017

5

John S Lazo

1 reference

21 June 2017

2

Peter Wipf

1 reference

21 June 2017

1

Elizabeth R Sharlow

1 reference

21 June 2017

4

Ahmet Bakan

1 reference

21 June 2017

3

Kelley E McQueeney

1 reference

21 June 2017

language of work or name

English

0 references

publication date

13 March 2014

1 reference

Expert Opinion on Investigational Drugs

21 June 2017

published in

1 reference

21 June 2017

volume

23

1 reference

21 June 2017

issue

5

1 reference

21 June 2017

page(s)

661-673

1 reference

The human phosphatase interactome: An intricate family portrait

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Modular evolution of phosphorylation-based signalling systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Protein tyrosine phosphatases in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Targeting protein serine/threonine phosphatases for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Protein Ser/Thr phosphatases--the ugly ducklings of cell signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

A phosphatase associated with metastasis of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

PRL-3, an emerging marker of carcinogenesis, is strongly associated with poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

PRL phosphatases as potential molecular targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

PRL-3 phosphatase is implicated in ovarian cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

AOM-induced mouse colon tumors do not express full-length APC protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Structure and biochemical properties of PRL-1, a phosphatase implicated in cell growth, differentiation, and tumor invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Structure of human PRL-3, the phosphatase associated with cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Structural insights into molecular function of the metastasis-associated phosphatase PRL-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Phosphatase activity, trimerization, and the C-terminal polybasic region are all required for PRL1-mediated cell growth and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

PRL PTPs: mediators and markers of cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Interaction of farnesylated PRL-2, a protein-tyrosine phosphatase, with the beta-subunit of geranylgeranyltransferase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

The metastasis-promoting phosphatase PRL-3 shows activity toward phosphoinositides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Phosphatase of regenerating liver-3 directly interacts with integrin β1 and regulates its phosphorylation at tyrosine 783

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Requirement of phosphatase of regenerating liver-3 for the nucleolar localization of nucleolin during the progression of colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Stathmin, a New Target of PRL-3 Identified by Proteomic Methods, Plays a Key Role in Progression and Metastasis of Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

PRL-3 activates NF-κB signaling pathway by interacting with RAP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase/phosphatase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

The essential role of FKBP38 in regulating phosphatase of regenerating liver 3 (PRL-3) protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Inhibitory activities of anthraquinones from Rubia akane on phosphatase regenerating liver-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Is Cdc25 a druggable target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Image-Based Chemical Screening Identifies Drug Efflux Inhibitors in Lung Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Targeting intracellular oncoproteins with antibody therapy or vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Comparative protein modelling by satisfaction of spatial restraints

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

UCSF Chimera--a visualization system for exploratory research and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Druggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe Molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

VMD: visual molecular dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

Using small molecules to target protein phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.892579

NAMD: a Parallel, Object-Oriented Molecular Dynamics Program

21 January 2018

1 reference

COCI

https://opencitations.net/index/coci/api/v1/citations/10.1177/109434209601000401

10.1517/13543784.2014.892579

22 October 2022

Identifiers

DOI

1 reference

21 June 2017

1 reference